Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine

Learn more about:
Related Clinical Trial
Preventative Intervention for Cholera for 7 Days Impact Study of Cholera Vaccination in Endemic Areas – Clinical Surveillance Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ in Nepalese Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults PXVX0200 (CVD103-HgR) vs Shanchol in Mali Cholera-Hospital-Based-Intervention-for-7-days A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi Single Dose Azithromycin in the Treatment of Adult Cholera Safety and Immunogenicity of a New Formulation of Euvichol® Cholera Anti-Secretory Treatment Trial PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Zinc Supplementation in Cholera Patients Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Pilot Introduction of Oral Cholera Vaccine in Orissa, India Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Immunity to Human Cholera in Bangladesh Ciprofloxacin Multiple Dose for Adult Cholera Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo Protective Immunity to Human Cholera in Bangladesh Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Oral Cholera Vaccine Delivery in Rural Bangladesh Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Mass Oral Cholera Vaccination in Zanzibar Cholera Vaccine Investment Strategy in Bangladesh Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Introduction of Cholera Vaccine in Bangladesh Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Evaluation of a Boosting Regimen With Oral Cholera Vaccine Single Dose Azithromycin to Prevent Cholera in Children Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Brief Title

Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine

Official Title

Immune Responses Following One Versus Two Doses of Killed Oral Cholera Vaccine in Eastern Kolkata, West Bengal, India

Brief Summary

      The purpose of this study is to compare the safety and immunogenicity of one and two doses of
      the killed oral cholera vaccine.
    

Detailed Description

      Cholera is an important public health problem worldwide, particularly in endemic areas of the
      developing world. In 2004, 101 383 cholera cases and 2345 deaths were reported to the WHO.
      Provision of safe water and food, adequate sanitation and improved personal and community
      hygiene are the main public health interventions against cholera. These measures cannot be
      implemented in the near future in the most cholera-endemic areas.

      Phase II trials of this reformulated killed oral cholera vaccine were performed in SonLa,
      Vietnam and Kolkata, India. Significant vibriocidal antibody responses were observed among
      vaccine recipients.

      Distribution of 2 doses of the cholera vaccine is often difficult in field settings and
      limits its utility in emergency situations, since an interval of 2 weeks is usually required
      between doses. Recent data from Vietnam suggests that greater vibriocidal responses following
      2 doses are elicited compared to previous formulations. Furthermore, in a study in Bangladesh
      comparing immune responses to the vaccine among children supplemented with vitamin A and
      zinc, seroconversion after the first dose was robust in all groups suggesting that one dose
      may be used in the control of cholera.

      Data regarding the immune response following one dose of this reformulated vaccine is
      currently unavailable. If a single dose of this vaccine is confirmed to be immunogenic to
      recipients, then this vaccine may be used more extensively for public health purposes,
      especially during times of outbreaks.

      The objective of this study is to confirm the safety of the killed oral cholera vaccine among
      adult and children volunteers.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Proportion of subjects exhibiting 4-fold or greater rises in titers of serum vibriocidal antibodies, relative to baseline

Secondary Outcome

 Geometric mean serum vibriocidal titers compared to baseline

Condition

Cholera

Intervention

Killed bivalent whole cell oral cholera vaccine

Study Arms / Comparison Groups

 1
Description:  Cholera Vaccine

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

160

Start Date

June 2007

Completion Date

August 2007

Primary Completion Date

August 2007

Eligibility Criteria

        Inclusion Criteria:

          -  Healthy adult male and non-pregnant female adults aged 18-40 years and healthy
             children aged 1-17 years

        All subjects must satisfy the following criteria at study entry:

          -  Male or female adult residents aged 18-40 years or children aged 1- 17 years who the
             investigator believes will comply with the requirements of the protocol (i.e.
             available for follow-up visits and specimen collection)

          -  For females of reproductive age, they must not be pregnant (as determined by verbal
             screening)

          -  Written informed consent obtained from subjects or their guardians, and written assent
             for children aged 12-17 years.

          -  Healthy subjects as determined by: medical history, physical examination, clinical
             judgement of the investigator.

        Exclusion Criteria:

          -  Ongoing serious chronic disease

          -  Immunocompromising condition or therapy

          -  Diarrhea (3 or more loose stools within a 24-hour period) 6 weeks prior to enrollment

          -  one or two episodes of diarrhea lasting for more than 2 weeks in the past 6 months

          -  one or two episodes of abdominal pain lasting for more than 2 weeks in the past 6
             months

          -  intake of any anti-diarrhoeal medicine in the past week

          -  abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in
             the past 24 hours

          -  acute disease one week prior to enrollment, with or without fever. Temperature > or =
             38 degrees C (oral) or axillary temperature > or = 37.5 degrees C warrants deferral of
             the vaccination pending recovery of the subject

          -  receipt of antibiotics in past 14 days

          -  receipt of live or killed enteric vaccine in last month

          -  receipt of killed oral cholear vaccine
      

Gender

All

Ages

1 Year - 40 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Sujit K Bhattacharya, , 

Location Countries

India

Location Countries

India

Administrative Informations


NCT ID

NCT00419133

Organization ID

C-8IR



Study Sponsor

International Vaccine Institute

Collaborators

 National Institute of Cholera and Enteric Diseases, India

Study Sponsor

Sujit K Bhattacharya, Principal Investigator, National Institute of Cholera and Enteric Diseases, India


Verification Date

December 2009